Sint-Niklaas

• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and ch … Recruiting
  2025-523009-14-00 4 2025-12-16 Bronchiectasis with chronic pseudomonas aeruginosa colonization
• A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting
  2024-514500-14-00 5 2025-12-15 Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting
  2025-521242-26-00 4 2025-11-27 Moderately to Severely Active Ulcerative Colitis
• A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting
  2024-519654-37-00 10 2025-11-07 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting
  2024-515884-69-00 5 2025-07-16 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 4 2025-05-16 Diffuse Large B-Cell Lymphoma (DLBCL)
• Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting
  2024-514465-18-00 9 2025-04-23 Advanced or Metastatic Non-Squamous NSCLC
• A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti … Recruiting
  2024-513053-69-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L … Recruiting
  2023-505311-20-01 5 2025-03-21 Metastatic Non-Small Cell Lung Cancer
• A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-515008-38-00 5 2025-02-14 Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
• A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting
  2023-509096-16-00 6 2024-07-31 Moderately to Severely Active Crohn’s Disease
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo … Recruiting
  2023-506308-24-00 10 2024-05-22 Recurrent or metastatic head and neck squamous cell carcinoma
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc … Recruiting
  2023-506703-26-00 5 2024-02-07 locally advanced rectal cancer
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma

Showing 25–48 of 118 trials